- Home
- CGNT vs RZLT Comparison
CGNT vs RZLT Comparison
Compare CGNT & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- RZLT
- Stock Information
- Founded
- CGNT 2020
- RZLT 2010
- Country
- CGNT Israel
- RZLT United States
- Employees
- CGNT N/A
- RZLT N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- RZLT Health Care
- Exchange
- CGNT Nasdaq
- RZLT Nasdaq
- Market Cap
- CGNT 617.3M
- RZLT 713.4M
- IPO Year
- CGNT N/A
- RZLT N/A
- Fundamental
- Price
- CGNT $8.00
- RZLT $8.87
- Analyst Decision
- CGNT Buy
- RZLT Strong Buy
- Analyst Count
- CGNT 2
- RZLT 6
- Target Price
- CGNT $14.00
- RZLT $14.50
- AVG Volume (30 Days)
- CGNT 254.2K
- RZLT 1.6M
- Earning Date
- CGNT 09-09-2025
- RZLT 11-06-2025
- Dividend Yield
- CGNT N/A
- RZLT N/A
- EPS Growth
- CGNT N/A
- RZLT N/A
- EPS
- CGNT N/A
- RZLT N/A
- Revenue
- CGNT $376,566,000.00
- RZLT N/A
- Revenue This Year
- CGNT $15.30
- RZLT N/A
- Revenue Next Year
- CGNT $11.30
- RZLT N/A
- P/E Ratio
- CGNT N/A
- RZLT N/A
- Revenue Growth
- CGNT 14.04
- RZLT N/A
- 52 Week Low
- CGNT $6.38
- RZLT $2.22
- 52 Week High
- CGNT $11.66
- RZLT $9.72
- Technical
- Relative Strength Index (RSI)
- CGNT 38.63
- RZLT 57.23
- Support Level
- CGNT $8.00
- RZLT $7.80
- Resistance Level
- CGNT $8.28
- RZLT $9.29
- Average True Range (ATR)
- CGNT 0.28
- RZLT 0.51
- MACD
- CGNT -0.02
- RZLT -0.10
- Stochastic Oscillator
- CGNT 7.04
- RZLT 55.63
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.